News

Piper Sandler Reaffirms Their Buy Rating on Abacus Life (ABL)
Piper Sandler analyst Crispin Love maintained a Buy rating on Abacus Life (ABL – Research Report) today and set a price target of $11.50. The ...
Abacus Global price target lowered to $11.50 from $13 at Piper Sandler
Piper Sandler lowered the firm’s price target on Abacus Global (ABL) to $11.50 from $13 and keeps an Overweight rating on the shares. The firm ...
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology ...